http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104761585-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_146f4e572b94712c7f4afb070fe2bae1
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-6561
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-6558
filingDate 2014-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d557300e9ff296bb786a6ac4ad174a00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4025769eb53b4db39c33f9daa94b170e
publicationDate 2015-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-104761585-A
titleOfInvention Substituted aminopyrimidines as inhibitors of EGFR tyrosine kinase
abstract The compounds and salts of the present invention inhibit kinases, particularly the epidermal growth factor receptor family (EGFR, erbB-2, erbB-4) and clinically important "gatekeeper" mutants of these kinases, and are useful in the treatment of Or to improve abnormal cell proliferative disorders, such as cancer.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10906901-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113121575-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023027518-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11098030-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106458969-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106279160-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106279160-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11267802-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019015463-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10513509-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10435388-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017036263-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016029839-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111542322-A
priorityDate 2014-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103153064-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013014448-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID163703592
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID408769177
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID408930567
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID147620182
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465360140
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467465301

Total number of triples: 40.